Aquestive Therapeutics Opens New Lab in New Brunswick
The company has moved its research operations to the H1 building at the HELIX project.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Does clustering pharmaceutical and research firms in your area improve the local economy?
Aquestive Therapeutics has established a new research and development hub at the HELIX project in New Brunswick. The Warren-based firm moved into a 5,000-square-foot lab suite on the 10th floor of the H1 building at 20 French St.
Why it matters
This move provides the company with specialized lab infrastructure and access to a growing life sciences community to support its collaborative research efforts. Simultaneously, the FDA has accepted the company's New Drug Application for its treatment, Anaphylm.
The company now occupies a 5,000-square-foot laboratory space on the 10th floor of the H1 building. This facility is part of a larger project designed to eventually feature three distinct towers.
The players
Aquestive Therapeutics
A pharmaceutical company based in Warren, New Jersey, that develops drug delivery platforms and treatments.
New Brunswick Development Corp.
An organization focused on revitalizing the urban landscape of New Brunswick through major development projects.
JLL
A global commercial real estate services firm that manages and markets specialized enterprise facilities.
The details
The H1 facility offers ready-to-use lab environments designed to reduce construction timelines and capital expenditures for life sciences tenants. JLL brokered the transaction for the suite, which positions Aquestive within the new New Jersey Innovation Hub.
Timeline
October 15, 2026: Move and FDA application acceptance announced.
March 15, 2027: FDA goal date for Anaphylm application.
Market Landscape
This move marks a significant expansion of the life sciences sector within New Jersey as companies seek out centralized research hubs. The presence of Aquestive at the HELIX project positions the firm within a growing competitive cluster of pharmaceutical innovation.
The establishment of this research hub may accelerate the development of new pharmaceutical treatments available to patients. Residents may also see increased job opportunities as the HELIX project continues to attract specialized talent to the area.
The takeaway
Companies are increasingly favoring move-in ready lab suites to lower the barriers to entry for critical research and development. Access to shared infrastructure allows firms like Aquestive to focus resources on drug development rather than facility construction.
What happens next
The FDA is scheduled to reach its goal date for the Anaphylm New Drug Application on March 15, 2027.
Further reading
Learn more about local industry growth on the New Brunswick Healthcare page.
Source note: This article includes information reported by NJBIZ.
Live Poll
Does clustering pharmaceutical and research firms in your area improve the local economy?
